Format

Send to

Choose Destination
Hum Vaccin Immunother. 2014;10(11):3146-52. doi: 10.4161/hv.29553.

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Author information

1
a Department of Urology ; Eberhard Karls University Tübingen ; Tübingen , Germany.

Abstract

Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine the beneficial properties of sufficient antigen-expression, autologous immune-stimulation and a high flexibility with respect to production and application. CV9103 and CV9104 are novel RNActive®-derived anticancer vaccines for the treatment of patients with prostate cancer. After successful phase I/II studies with documentation of good tolerability and favorable immune-activation of CV9103, the vaccine CV9104 is currently undergoing clinical testing in specific clinical settings such as castration resistant prostate cancer and as a neoadjuvant agent in men with high risk prostate cancer prior to surgery. This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.

KEYWORDS:

CRPC; RNActive; immunotherapy; mRNA; metastatic; prostate cancer; vaccination

PMID:
25483661
PMCID:
PMC4514038
DOI:
10.4161/hv.29553
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center